Novo Nordisk A/S (NYSE:NVO) Stock Position Lowered by Juncture Wealth Strategies LLC

Juncture Wealth Strategies LLC decreased its holdings in Novo Nordisk A/S (NYSE:NVO) by 25.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 3,769 shares of the company’s stock after selling 1,289 shares during the period. Juncture Wealth Strategies LLC’s holdings in Novo Nordisk A/S were worth $324,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Natixis Advisors LLC grew its stake in Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC raised its position in Novo Nordisk A/S by 45.3% during the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after acquiring an additional 19,870 shares in the last quarter. Versant Capital Management Inc acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $86,000. Talbot Financial LLC acquired a new position in shares of Novo Nordisk A/S during the 4th quarter worth $4,066,000. Finally, Zions Bancorporation N.A. raised its holdings in shares of Novo Nordisk A/S by 57.0% during the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after purchasing an additional 6,726 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NVO has been the topic of several analyst reports. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Trading Up 8.4 %

Shares of NVO stock opened at $87.94 on Friday. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The stock has a market cap of $394.65 billion, a price-to-earnings ratio of 28.46, a P/E/G ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm has a fifty day moving average of $95.35 and a 200-day moving average of $115.17.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.